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Abstract
Micafungin, a new echinocandin antifungal agent, has been widely used for the treatment of
various fungal infections in human populations. Micafungin is predominantly cleared by biliary
excretion and it binds extensively to plasma proteins (>99.5%). Micafungin body weight-adjusted
clearance is higher in neonates than in adults, but the mechanisms underlying this difference are
not understood. Previous work had revealed the roles of sinusoidal uptake (Na+-taurocholate co-
transporting peptide, NTCP; organic anion transporting polypeptide, OATP) as well as canalicular
efflux (bile salt export pump, BSEP; breast cancer resistance protein, BCRP) transporters in
micafungin hepatobiliary elimination. In the present study, the relative protein expression of
hepatic transporters was compared between liver homogenates from neonates and adults. Also, the
extent of micafungin binding to serum from neonates and adults was measured in vitro. The
results indicate that relative expression levels of NTCP, OATP1B1/3, BSEP, BCRP, and MRP3
were similar in neonates and in adults. However, micafungin fraction unbound (fu) in neonatal
serum was about 8-fold higher than in adult serum (0.033 ± 0.012 versus 0.004 ± 0.001,
respectively). While there was no evidence for different intrinsic hepatobiliary clearance of
micafungin between neonates and adults, our data suggest that age-dependent serum protein
binding of micafungin is responsible for its higher clearance in neonates compared to adults.
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Introduction
Micafungin is a new semi-synthetic echinocandin-type antifungal drug that has been widely
used for the treatment of various fungal infections in human populations. Pharmacokinetic
studies with 14C-micafungin determined that approximately 90% of the plasma clearance
occurs via biliary elimination of the parent drug [1], whereas urinary excretion is a minor
elimination route in human and rat [2–4]. Like caspofungin and anidulafungin, micafungin
Corresponding Author: Pieter Annaert, PhD, Laboratory for Pharmacotechnology and Biopharmacy, Department of Pharmaceutical
Sciences, Katholieke Universiteit Leuven, O&N2, Herestraat 49-bus 921, 3000 Leuven, Belgium., pieter.annaert@pharm.kuleuven.be,
Phone: +32-16-33 03 03, Fax: +32-16-33 03 05.
NIH Public Access
Author Manuscript
Biopharm Drug Dispos. Author manuscript; available in PMC 2012 May 1.
Published in final edited form as:













is a peptide-like compound. Due to the presence of a sulfate group, micafungin is negatively
charged at physiological pH (see Figure 1). Micafungin displays high plasma protein
binding (>99%) in humans and animals [4].
Pharmacokinetic parameters of micafungin were determined in several human age groups:
neonates < 1 month old, children <8 years of age, adolescents, and adults [5,6]. Micafungin
was found to have a higher body weight-adjusted clearance in neonates than older groups.
The necessity to use higher body-weight adjusted doses in neonates in order to achieve
therapeutic plasma concentrations was recently confirmed by a population pharmacokinetic
analysis [7]. As of today, no studies have been conducted to elucidate the cause of this age-
difference in the disposition of micafungin in humans.
In order to obtain better insight in the age-dependent disposition of micafungin, it was
crucial to first understand the clearance mechanisms in the adult population. In this context,
we have recently conducted in vitro transport studies with micafungin in sandwich-cultured
human hepatocytes (SCHH) [8], which revealed the following: a) the sinusoidal uptake
transporter Na+-taurocholate co-transporting peptide (NTCP, SLC10A1) and the canalicular
efflux transporter Bile Salt Export Pump (BSEP, ABCB11) were found to mediate the
hepatobiliary disposition of micafungin; b) Breast Cancer Resistance Protein (BCRP,
ABCG2), Multidrug Resistance Associated Protein 3 (MRP3, ABCC3), and Organic Anion
Transporting Polypeptide (OATP, SLCO) were found to modestly associate with the
disposition of micafungin in SCHH; c) by using B-CLEAR® technology (Qualyst Inc.,
Research Triangle Park, NC) [9–11], in vivo plasma and biliary clearance of micafungin
were calculated based on the in vitro data obtained in SCHH and found to be in agreement
with the clinical data. Because of ethical considerations, it is almost impossible to obtain
fresh liver tissue from neonates suitable for establishing SCHH, which would support
investigating transporter-mediated disposition of micafungin and predicting in vivo
hepatobiliary clearance like in adults. However, it was possible to obtain frozen liver tissue
samples from neonates (and adults) to support determining the protein expression of hepatic
drug transporters. In addition, because protein binding is known to influence drug
distribution and drug clearance, and because it is variable as a function of age [12–15], the
extent of micafungin serum binding in neonates was determined in vitro.
In this study, we calculated in vivo hepatobiliary clearance of micafungin in neonates based
on: a) the in vitro intrinsic clearance in adults as determined previously [8]; b) scaling
factors applicable for human neonatal liver; and c) micafungin fraction unbound in serum of
neonates. We showed that the calculated in vivo plasma and biliary clearance in neonates are
in agreement to those observed in clinic. Our data provide evidence for the mechanism
underlying higher clearance of micafungin in neonates compared to adults.
Materials and Methods
Chemicals and Reagents
Micafungin–sodium was a gift from Dr. John Perfect at Duke University. Serum samples
from neonates or adult (n=6/group) were provided by Dr. Daniel Benjamin at Duke Center
Research Institute. Frozen liver from neonates and adults (5 samples per group) were
obtained from the Comparative Human Tissue Network (CHTN) (Columbus, OH) under an
approved UNC-Chapel Hill Institutional Review Board protocol. NuPAGE 4–20% Bis-Tris
gel and all other gel electrophoresis and Western blot reagents and supplies were purchased
from Invitrogen (Carlsbad, CA). Primary antibodies against human BSEP [ABCB11] (F-6),
NTCP [SLC10A1] (M-130) and OATP1B1 [SLCO1B1] (and OATP1B3 [SLCO1B3] to a
lesser extent) (N-16) were purchased from Santa Cruz (Santa Cruz, CA), while those against
MRP3 [ABCC3] (M3II-9), BCRP [ABCG2] (BXP-53), and GAPDH were purchased from
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Alexis (San Diego, CA). Horseradish peroxidase-conjugated secondary antibody suitable for
each primary antibody and the chemi-luminescent substrate SuperSignal® West Dura were
purchased from Pierce Chemical (Rockford, IL).
Protein Expression of Drug Transporters in Liver Tissues from Neonates and Adults
Frozen liver tissues from neonates (postnatal age 0–1 month), and from adults (older than 18
years) were homogenized in 1.15% KCL buffer, pH 7.4 (1:3, w/v) and crude homogenates
were prepared after centrifugation at 800 rpm for 3 min. Protein concentration in crude liver
homogenates was determined by the bicinchoninic acid method against bovine serum
albumin standard, and homogenates at 1mg/ml were prepared in sample buffer containing a
protease inhibitors cocktail (Sigma-Aldrich, St. Louis, MO). Western blot analysis for the
expression of transport proteins was performed by separating the transport proteins in liver
homogenate samples loaded on SDS page gel (20 μl/well) with gel electrophoresis and the
proteins were then transferred to nitrocellulose membranes according to the vendor’s
instructions (Invitrogen, Carlsbad, CA). Primary antibodies against human NTCP, BSEP,
OATP1B1/3, MRP3, BCRP, GAPDH were appropriately diluted (1:200, 1:200, 1:200,
1:200, 1:500, and 1:4000, respectively) and incubated with the membrane for 2 hr at 37°C.
Horseradish peroxidase-conjugated secondary antibody suitable for each primary antibody
was cross-reacted with the transporter protein-primary antibody complex; immunoreactive
protein bands were detected using a Bio-Rad VersaDoc imaging system (Bio-Rad, Hercules,
CA). For quantitative determination of protein expression, three density measurements of
each band corresponding to BSEP, OATP1B1/3, MRP3, BCRP, GAPDH (molecular weight
190 kDa, 90 kDa, 170 kDa, 70 kDa, 35 kDa, respectively) were determined and the mean
density was normalized to the mean density of the GAPDH band (used to adjust expression
based on actual loaded protein samples). Relative expression of the four transporters to
GAPDH in each liver homogenate sample in the neonatal or adult group was determined for
each of the five liver homogenate samples per group. The mean was expressed per kg body
weight based on the following scaling parameters: 35 and 70 mg protein/gram liver in
neonates and adult (experimentally determined), respectively; 120 g and 1500 g average
liver weight in neonates or adult (data listed by Björkman [16]), respectively; 3 kg and 70 kg
average body weight in neonates and adult (data listed by Björkman [16]), respectively. The
relative protein expression in neonates was expressed as percent of the mean expression in
adult samples.
Micafungin Serum Fraction Unbound in Neonates and Adults
Micafungin fraction unbound in serum from human neonates or adults was determined by
equilibrium dialysis according to a modified method described by Kalvass and Maurer [17].
Briefly, Spectra/Por® 2 dialysis membranes (Spectrum Laboratories Inc., Rancho
Dominguez, CA) were conditioned in water for 15 min, followed by 30% ethanol for 15
min, and sodium phosphate buffer (100 mM, pH 7.4) for 15 min. Serum samples from
neonates (prenatal age 23–40 weeks of gestation; postnatal age 1–52 days; body weight 0.6–
3.5 kg) (n=6) or adults (n=6) were spiked with micafungin (10 μM) and 70 μl aliquots of
each sample were loaded into a 96-well equilibrium dialysis apparatus (HTDialysis, Gales
Ferry, CT) and dialyzed against an equal volume of sodium phosphate buffer (100 mM, pH
7.4). The 96-well equilibrium dialysis apparatus was incubated for 4.5 hr with orbital
shaking (100 rpm) at 37°C. These equilibrium dialysis conditions were found to be
sufficient for micafungin to reach equilibrium. Aliquots from dialyzed samples (serum side
and buffer side) were processed and the concentrations of extracted micafungin in both
serum and buffer matrices were determined based on calibration curves of micafungin
prepared in the corresponding matrix. Micafungin fu was determined according to Equation
1.
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An HPLC method was developed to separate micafungin and diclofenac (internal standard)
using a C8 XTerra® column (3 × 100 mm, 3.5μ Waters); a linear gradient of mobile phase
A:B (v/v) was used starting from 70:30 at 0 min to 5:95 in 9 minutes at a flow rate of 0.5 ml/
min, where (A) was 5 mM ammonium acetate with 0.1% formic acid, pH 4.0, and (B) was
acetonitrile with 0.1% formic acid. Micafungin was detected by fluorescence emission at
464 nm (excitation at 273 nm), while diclofenac was detected by UV at 280 nm; the
retention times were 5.5 min for micafungin and 6.3 min for diclofenac. The method was
linear for a micafungin concentration range of 0.1–5 μM. Accuracy and precision of the
method were 12% and 3.3% for 0.3 μM and 0.2% and 2.8% for 2.5 μM, respectively.
Data Analysis
Micafungin fu was determined from the following equation:
(Equation 1)
The fu values in six neonates were plotted against the age of gestation at birth (in weeks) or
against postnatal age at birth (in days) of each subject.
In vivo micafungin plasma and biliary clearance values were predicted based on previously
obtained in vitro data [8], and the serum binding data obtained in the present study. The in
vitro intrinsic biliary clearance (ml/min/mg protein) and in vitro intrinsic accumulation
clearance were first scaled to kg body weight using the parameters listed in Table 1 as
published by Björkman et al. [16]. In the absence of albumin during in vitro incubations [8],
unbound intrinsic biliary clearance (intrinsic Cl′biliary) and unbound intrinsic plasma
clearance (intrinsic Cl′plasma) were assumed to correspond to in vitro intrinsic biliary
clearance and in vitro intrinsic accumulation clearance, respectively. The calculated in vivo
biliary clearance (Clbiliary) and in vivo plasma (accumulation) clearance (Clplasma) values
were calculated according to the well-stirred model of hepatic disposition, assuming a
micafungin blood/plasma concentration ratio of 1:
(Equation 2)
(Equation 3)
where QH represents the hepatic plasma flow rate. The QH values in neonate and adult are
listed in Table 1.
Statistical Analysis
An unpaired t-test (assuming unequal variance) was performed to determine the significance
of the difference in micafungin fu between neonates and adults.
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Protein Expression of Drug Transporters in Liver Tissues from Neonates and Adults
The immunostaining bands corresponding to NTCP, BSEP, BCRP, MRP3, and the hepatic
isoforms belonging to the OATP1B subfamily in five neonatal liver homogenate samples
(N1–N5) and in five adult liver homogenate samples (A1–A5) are shown in the upper part of
Figure 2. As illustrated in the lower panel of Figure 2, the protein expression levels of these
transporters in neonates, relative to GAPDH and expressed per kg body weight, were
between 84 and 115% of adult levels. No statistically significant differences were observed
in transporter expression levels between neonates and adults.
Serum Fraction Unbound of Micafungin in Neonates and Adults
Using equilibrium dialysis, micafungin fu was determined as function of time and drug
concentration (data not shown). In neonates, the mean fu from six different neonatal samples
conducted at three different days was found to be 0.033 ± 0.017 (96.7% bound) compared to
a mean fu value of 0.004 ± 0.003 (99.6% bound) in adult (Figure 3). The difference of fu
between neonates and adults is statistically significant (P <0.001). Figure 4 illustrates the
individual fu values in neonates along with the postgestational age at birth as well as the
postnatal age. The highest fu was observed for the full term subjects 1 and 3 (40 weeks
postgestation), while lower fu values were found for premature subjects 2 and 4 (24 and 31
weeks of gestation, respectively). The lowest micafungin fu was observed for subject 2,
which is not only the most premature, but also the oldest (52 days after birth) baby.
These results indicate that micafungin fu in neonate serum is higher than in adult serum.
These results also indicated that, while there appears to be a weak relationship between
postgestational age at birth and fu, there is no evidence for a relationship between postnatal
age in neonates and fu.
Prediction of in vivo Plasma and Biliary Clearance of Micafungin in Neonates
In vitro intrinsic accumulation Cl and in vitro intrinsic biliary Cl of micafungin have
recently been determined using sandwich-cultured human hepatocytes from adult liver
donors [8], and were 23.5 ± 1.6 and 14.0 ± 9.0 μl/min/mg, respectively. To estimate in vitro
intrinsic clearance values for micafungin in neonates, in vitro intrinsic clearance values of
adults were used, given that expressions of drug transporters associated with the clearance of
micafungin in neonates and adults were comparable (Figure 2). As illustrated in Table 1,
intrinsic clearance values were scaled to in vivo intrinsic clearance using neonate-based
scaling factors as reported [16,18]. In vivo intrinsic clearance values were then used to
calculate in vivo clearance values based on the well-stirred model (Equation 2 and Equation
3), taking into account micafungin fu (as determined in the present study) as well as adult/
neonatal values for QH. The results shown in Table 1 illustrate a good agreement between
the observed and calculated plasma clearance values. In addition, the calculated clearance
values in neonates were 3-fold higher than in adults as it has been observed in clinic.
Discussion
Micafungin, which is used to treat life-threatening fungal CNS infection in neonates and
young infants, is mainly cleared into the bile [1]. Surprisingly, the clearance of micafungin
in neonates, the human population generally displaying immature drug metabolizing
enzymes and drug transporter function, is reported to be three times that of adults. Because it
undergoes biliary clearance, we hypothesized that the higher clearance of micafungin in
neonates might be due to the higher drug uptake and/or secretion by sinusoidal and
canalicular liver transporters. The transporters that mediate the uptake and secretion of
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micafungin were identified in our previous in vitro mechanistic study using human
sandwich-cultured hepatocytes prepared from fresh liver of adult donors [8]. These in vitro
data confirmed the unique utility of this in vitro model system in exploring the mechanisms
of hepatic uptake and biliary excretion of endogenous and exogenous compounds and in
predicting in vivo biliary clearance of drugs [9–11,19–22]. In our previous study, we have
indeed reported that in in vitro hepatic accumulation of micafungin in adult human
hepatocytes occurred mainly by transporter-mediated mechanisms. The uptake of
micafungin into the hepatocytes was mediated by NTCP ≫ OATP, whereas the biliary
excretion involved the canalicular transporters BSEP > BCRP. The results also suggested a
role for the sinusoidal efflux transporter MRP3, in the hepatic disposition of micafungin.
Unfortunately, because of ethical considerations, it is nearly impossible to obtain human
neonatal liver tissue suitable for establishing hepatocyte cultures. Therefore, we considered
another approach to obtain better insight into the age-dependent clearance of micafungin. By
measuring the protein expression of NTCP, BSEP, BCRP, MRP3 and both hepatic OATP1B
isoforms in neonatal versus adult liver homogenates, we pursued to make a semi-
quantitative assessment regarding the possible age-dependent activity of these transporters.
A few studies on the ontogeny of transporter expression and function have indeed
demonstrated that transporter protein expression levels correlate with function. For example,
in a developmental mouse model, Pinto et al. [23] showed that digoxin accumulation in
brain, kidney, and liver agreed with the expression level of the Mdr1a gene encoding for the
P-gp efflux transporter in an age-dependent manner. Goralski et al. [24] have shown an
agreement between the expression and function of transporters by demonstrating that
deficient Mdr1a/b expression in neonatal mouse brain resulted in enhanced accumulation of
digoxin and cyclosporin in neonatal mice compared to adult mice. As mentioned earlier, we
have previously shown that micafungin is predominantly relying on the bile salt transporters
NTCP and BSEP for its hepatobiliary elimination. At the uptake level, our data support
comparable expression of the main micafungin transporter NTCP between neonates and
adults. Previous work by Hardikar et al. [25] in rats, indicated that Ntcp protein was
expressed as early as postnatal day 1, and the expression levels on day 1 and day 7
(equivalent to 1 month human neonate) postnatal liver were also comparable to those in
adults. Furthermore, as shown in this study (see Figure 2), also BSEP exhibits comparable
expression in neonates and in adults. This result was consistent with previous data on
quantitative expression of BSEP and other canalicular transport proteins in human fetal,
pediatric and adult livers [26,27]. In these studies, the authors reported that BSEP protein
was expressed in fetus and pediatric human liver at the same level as adult, however, in
fetus, the localization of BSEP was found to be at both the canalicular and cytosolic
locations. In general, very limited information on the ontogeny of drug transporters in
human, not only at the functional level, but also at the expression level has been obtained.
Studies on the age-dependent expression and localization of MDR1/P-gp in human brain
[28] and small intestine [29] are exceptions. In the rat, Gao et al. observed that the
canalicular transporter Bsep was detected at the canalicular membrane before birth but
reached adult expression levels by postnatal day 12 (day 7 in neonatal rat is equivalent to
neonate in human) [30]. The authors indicated that by day 12, hepatocytes were fully
polarized and localization of transporters (at either canalicular or sinusoidal membranes)
was comparable to what was observed in adult hepatocytes. They also reported that the
development of polarized hepatocyte membranes and expression of major bile salt
transporters Bsep and Ntcp occurs shortly before birth and that correlated with the
development of the enterohepatic circulation of bile salts. Therefore, full development of
this excretion route early in neonatal life indicates that age-dependent expression (and thus
function) of these transporters may not explain the age-dependent clearance of micafungin.
It follows that the similarity in the expression of these transporters between neonates and
adults can confidently be used to quantitatively estimate micafungin hepatic clearance in
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neonates, based on the in vitro intrinsic uptake and biliary clearance that we previously
measured for adults.
Because protein binding is known to affect drug clearance, especially of those drugs that
possess high protein binding like micafungin, we measured fu of micafungin in vitro in
serum from neonates and adults; as mentioned in the results section, we observed a
significantly higher unbound fraction in neonates. McNamara and Alcorn [12] have shown
that for lipophilic drugs, ~ 2-fold higher fu values can be expected in pediatric plasma
compared to adults based on lower plasma protein concentrations in neonates than in adults.
However, the model that was developed by McNamara and Alcorn [12] under-predicted the
fu value of micafungin in neonates compared to the value we have experimentally measured
in the present study using in vitro equilibrium dialysis in neonate serum. One explanation for
the 8-fold higher fu in neonates compared to adult could be that micafungin binds not only to
plasma proteins [more likely to albumin than gamma-globulin (31)], but also to lipoproteins,
cholesterol, or other serum components that were found to be higher in adult serum than in
neonate serum [12,15]. Furthermore, the physicochemical properties of a peptide like
micafungin differ substantially from those of the model drugs used to establish the model
obtained by McNamara and Alcorn [12]. Due to limited availability of clinical
pharmacokinetic data in neonates, it is presently unclear to what extent lower protein
binding (higher free fraction in the blood) in neonates versus adults is a more common
reason for enhanced drug clearance in neonates. In addition, in contrast to what we have
presently observed for micafungin, the enzyme or transporter-mediated elimination
pathways of many drugs show pronounced age-dependency [32–34], thus complicating the
interpretation of possible effects of altered protein binding on overall in vivo drug
elimination. Caspofungin, which is another echinocandin antimycotic, also shows a small
unbound fraction in blood (about 3.5%) [35]. However, in contrast to micafungin,
caspofungin clearance in neonates (< 3 months) is significantly lower as compared to older
children (2-11y) and, to a lesser extent, as compared to adults [36]. For this reason, the
caspofungin recommended dose (normalized for body surface area) in neonates is about half
the dose used in adults. While the caspofungin free fraction in neonate serum has not been
measured, there is clearly no evidence that reduced caspofungin serum binding in neonates
plays an important role in altered caspofungin disposition in this age group. The
immunosuppressant cyclosporin A is another cyclic peptide exhibiting low unbound fraction
in blood as well as age-dependent pharmacokinetics, with 2-fold lower oral clearance in
neonates compared to older children and adults [37]. However, cyclosporin A shows a
complex binding profile in plasma (mainly to lipoproteins) as well as in blood (distribution
to erythrocytes) [38], while the ontogeny of this behavior has not been investigated. From a
more general point of view, the clinical relevance of plasma protein binding alterations
(most often considered from a binding competition perspective) as a mechanism underlying
drug clearance differences should not be overestimated [39–40]. Nevertheless, the 8-fold
increase in unbound micafungin in neonates as compared to adults is substantial, especially
in light of the less pronounced effects reported previously for a list of more than 25 drugs
[12]. In this list, the largest differences were reported for propranolol, quinidine and
verapamil, which all exhibited 3–4 fold increased unbound fractions in neonates compared
to adults. Unfortunately, clinical PK data in children, especially neonates, are very limited or
lacking. In the case of verapamil, Piovan et al. [41] reported plasma levels of verapamil and
its metabolite norverapamil in children between 15 days and 17 years. Their data
demonstrated gradually increasing norverapamil/verapamil levels from birth onwards to
reach a plateau by the age of 1 year, which then remained constant until adulthood. There
was no evidence for any effect of an increased free verapamil fraction on verapamil
clearance in neonates as compared to older children. This further suggests that for many
drugs, altered plasma protein binding in neonates does not have a substantial impact on
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clearance. In addition, even when some effect would exist, it may not be easily observed due
to concomitant changes in activity of drug metabolizing enzymes and transporters [32–34].
As we have indicated in the results section (Table 1), the in vivo plasma clearance and
biliary clearance values we calculated for micafungin in neonates were found to be three
times those in adults, thus mirroring the difference in clearance between neonates and adults
observed in the clinic. Since the calculated in vivo clearance was based on the adult intrinsic
clearance values, the higher fu value of micafungin in neonates, is the factor that explains the
higher in vivo clearance of micafungin in neonates. According to the well-stirred model
applied here, neither the different relative liver protein content (mg/kg body weight) nor the
higher QH in neonates, contributed to the higher in vivo clearance of micafungin in neonates.
To summarize, similar protein expression of liver drug transporters, but higher fu of
micafungin in neonates compared to adults have been determined by using in vitro methods
and biological samples from both age groups. The in vivo plasma and biliary clearance in
neonates calculated based on in vitro transport data of adults generated by SCHH indicated
that fu may be the key contributor to the higher clearance of micafungin observed in
neonates, however a definitive conclusion could not be made with the results that have been
presented in this study. For instance, a possible role of one or more transporters that differ
from those identified in adults may still be involved in micafungin disposition in neonatal
liver. In addition, we assumed that neonates display no additional enzymatic clearance
mechanisms for micafungin as compared to adults. However, Hope et al. [7] recently
reported that substantially higher levels of the metabolite M5 were measured in neonates as
compared to adults. It is clear that the existence of a neonate-specific metabolic pathway for
micafungin could also contribute to its higher clearance, but further research is required in
this respect. The extent of renal excretion of micafungin (and/or) metabolites in neonates has
not been measured. However, based on mass balance data obtained in adults, and based on
the fact that no dose adjustments are needed in patients with renal impairment [7], renal
micafungin elimination was demonstrated to play a very minor role as opposed to fecal
elimination. This suggests that the several fold higher clearance in neonates compared to
adults is unlikely to be due to (much) enhanced renal clearance in neonates compared to
adults. Future non-clinical work in sandwich-cultured hepatocytes from juvenile animals or
using apical and basolateral membrane vesicles prepared from human neonatal frozen liver
should be conducted in order to ultimately understand all mechanisms underlying altered
micafungin disposition in neonates.
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MRP2 and MRP3 Multidrug Resistance-associated Protein 2 and 3
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OATP Organic Anion Transporting Polypeptide
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QH hepatic blood flow
SCHH Sandwich-Cultured Human Hepatocytes
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Expression of Transporter Proteins in Liver from Human Neonates and Adults. Western blot
analysis on liver homogenates from neonates and adults was used to determine the relative
expression of hepatic transporters involved in micafungin uptake and biliary excretion. The
top parts of panel A and panel B depict the protein expression bands in five neonate samples
(N1–N5) and in five adult samples (A1–A5) for uptake and efflux transport proteins,
respectively. GAPDH protein expression was measured for normalization. The bottom parts
of both panels represent the mean (± SD) of GAPDH-normalized expression of the
transporters in neonates (per kg body weight) relative to protein expression (per kg body
weight) in adults where adult expression is 100%. Samples N3 and A5 were excluded from
densitometric analysis for NTCP due to irregular band shape.
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Micafungin Fraction Unbound in Serum from Human Neonates Compared to Adults.
Fraction unbound in serum from neonates and adults was determined by equilibrium dialysis
as discussed in the methods section. Bars represent the mean (±SD) of values from 6
subjects/group. Statistical significance indicated by ***, P <0.001 based on the unpaired t-
test (unequal variance).
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Micafungin Fraction Unbound in Serum from Neonates. Grey triangles (▲) represent the fu
(mean ± SD for three determinations) of micafungin in each subject. Each subject’s
postnatal age (◆) or postgestational age at birth (■) are also plotted. The mean value of fu
for the six subjects is represented by a dashed line (--).
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Table 1
Calculation of in vivo Plasma and Biliary Clearance of Micafungin in Adults and Neonates
Physiological Parameters & Scaling Factors Adult* Neonate
fu 0.004 0.033
mg protein/g liver 71 24**
g liver/kg body weight 26 43***
QH, ml/min/kg 21 73***
Observed Plasma Cl (ml/min/kg) 0.229 0.622#
Intrinsic Accumulation Cl (ml/min/mg) 0.024 ± 0.002 0.024 ± 0.002
Intrinsic Plasma Cl (ml/min/kg) 43.4 ± 3.0 24.3 ± 2.6
Calculated Plasma Cl (ml/min/kg) 0.175 ± 0.012 0.793 ± 0.085
Observed Biliary Cl (ml/min/kg) 0.160 Unknown
Intrinsic Biliary Cl (ml/min/mg) 0.014 ± 0.009 0.014 ± 0.012
Intrinsic Biliary Cl (ml/min/kg) 25.5 ± 15.7 14.3 ± 8.8
Calculated Biliary Cl (ml/min/kg) 0.101 ± 0.062 0.467 ± 0.287
Intrinsic clearance values were generated as described in the methods section. Intrinsic biliary clearance was determined using B-CLEAR®
technology Qualyst, Inc.).
*
Yanni et al. [8];
**
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